PFA startup founded by industry veteran to share first-in-human data at Heart Rhythm 2025
Field Medical, a California-based pulsed field ablation (PFA) company founded in 2022, is set to receive significant attention at Heart Rhythm 2025, the Heart Rhythm Society’s annual meeting in San Diego.
The company’s proprietary PFA technology, the FieldForce Ablation System, includes a high-voltage focal PFA catheter designed to deliver pulses in a fraction of a second and treat a variety of cardiac arrhythmias. The system will be involved in a total of eight different presentations at Heart Rhythm 2025, including multiple live case demonstrations and poster sessions.
The most highly anticipated presentation involving Field Medical’s technology, meanwhile, is a late-breaking clinical trial presented by Vivek Reddy, MD, a renowned electrophysiologist with the Mount Sinai Health System in New York City. On April 27, Reddy will share first-in-human data highlighting the FieldForce Ablation System’s safety and effectiveness in patients with scar-related ventricular tachycardia (VT).
Click here for a full list of Heart Rhythm 2025 presentations scheduled to feature the FieldForce Ablation System.
“For decades, VT has challenged even the most skilled electrophysiologists due to the complexity of the scar substrate,” Steven Mickelsen, MD, CEO and founder of Field Medical, said in a statement. “With FieldForce, we're not just iterating—we're redefining what's possible. This new focal PFA system has the potential to bring PFA to the areas of greatest unmet need in electrophysiology, and the momentum we're seeing at Heart Rhythm 2025 reflects that.”
Mickelson is already a veteran of the PFA space. He previously founded Farapulse, which Boston Scientific later acquired for more than $400 million.
The FieldForce Ablation System has not yet been approved by the U.S. Food and Drug Administration.
More momentum: Field Medical raised $40 million in financing
The busy weekend at Heart Rhythm 2025 follows news that Field Medical just raised $40 million in Series A financing. The funds are expected to go toward completing two pilot studies focused on the safety and effectiveness of the company’s technology and the ongoing development of the FieldForce Ablation System.
“We are encouraged by the strong support and confidence from both new investors and our reinvesting seed-round investor base,” said Oskar Dadason, Field Medical’s chief financial officer, said in a separate statement. “This funding enables us to execute our strategic plan with speed and focus as we transition from early-stage innovation into commercial readiness.”
Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.